<br>        Inclusion Criteria:<br><br>          1. Subject is male or female and aged 12-65 years.<br><br>          2. Subject has at least eight days with at least one myoclonic seizure over the two<br>             months Baseline Period. Myoclonic seizures must occur in the context of IGE and may be<br>             accompanied by other primary generalized seizures, provided these are also consistent<br>             with a diagnosis of Idiopathic Generalized Epilepsy (IGE).<br><br>          3. Subject (or parent/caregiver, for subjects below the age of consent) is willing to<br>             sign an informed consent form. Subjects below the age of consent in their country,<br>             must where appropriate be willing to give informed (written or verbal) assent.<br>             Subjects from the age specified in local regulations will be required to sign an<br>             appropriate informed consent form.<br><br>          4. Subject is taking a stable regimen of one or two other AEDs for at least two weeks<br>             prior to Visit 1 (start of the Baseline Period).<br><br>          5. Subject has a clinical diagnosis of any type of idiopathic generalised epilepsy (IGE)<br>             which has myoclonic seizures (and which may be accompanied by other generalised<br>             seizure types), according to the International League Against Epilepsy (ILAE)<br>             Classification of Epileptic Seizures (1981) and the ILAE Classification of Epilepsies<br>             and Epileptic Syndromes (1989). Diagnosis should have been established by clinical<br>             history, electroencephalogram (EEG) and computed tomography/magnetic resonance imaging<br>             (CT/MRI) of the brain consistent with idiopathic generalised epilepsy. A CT/MRI scan<br>             should have been performed within five years of the screening visit or, if not<br>             available from this period, should be performed in the Baseline Period.<br><br>          6. EEG should have been performed within one year of the screening visit or, if not<br>             available from this period, should be performed in the Baseline Period.<br><br>          7. Female subjects are pre-menarchal, or if of childbearing potential, are not pregnant<br>             or lactating, or are post-menopausal.<br><br>          8. Female subjects of childbearing potential = 18 years must abide by one of the<br>             following medically acceptable contraceptive measures: oral contraception pill,<br>             contraceptive injections, implants or patches, intrauterine device in place for at<br>             least three months or vasectomised partner or abstinence throughout the study.<br>             Subjects <18 years and of childbearing potential must be either abstinent or willing<br>             to use one of the medically appropriate forms of contraception for the duration of the<br>             study.<br><br>        Exclusion Criteria:<br><br>          1. Subject has progressive or focal neurological disease (as determined by preexisting<br>             brain imaging such as CT or MRI performed maximally five years before the screening<br>             visit), or clinically significant organic disease.<br><br>          2. Subject has a history of, or results of clinical investigations (including EEG data)<br>             that are suggestive of, partial seizures as defined by the ILAE, including generalised<br>             tonic clonic seizures which are suspected to be secondarily generalised.<br><br>          3. Subjects with cryptogenic or symptomatic generalised epilepsy.<br><br>          4. Subjects with psychogenic seizures.<br><br>          5. Subject has a history of convulsive status epilepticus within a year of screening<br>             while complying with AEDs.<br><br>          6. Subject has a history of renal calculi or renal insufficiency (above the upper normal<br>             limits of creatinine).<br><br>          7. Subject has a known diagnosis of human immunodeficiency virus (HIV) or hepatitis B or<br>             C.<br><br>          8. Subject has a predisposing condition that might interfere with absorption,<br>             distribution, or excretion of zonisamide.<br><br>          9. Subject has a history of sensitivity to sulfonamide drugs or to zonisamide or any of<br>             its excipients.<br><br>         10. Subject has a recent history of excessive alcohol use or drug abuse.<br><br>         11. Subject has a history of suicide attempt in the five years before the screening visit.<br><br>         12. Subject has abnormal screening laboratory values that are clinically significant.<br><br>         13. Subject has a history of demonstrated non-compliance with treatment, or the subject or<br>             parent/caregiver can be reasonably expected not to be compliant with study procedures<br>             or to complete the study.<br><br>         14. Subject has participated in a study of an investigational drug or device within 30<br>             days prior to screening.<br><br>         15. Subject has received previous treatment with zonisamide.<br><br>         16. Subject is treated with ketogenic diet or vagus nerve stimulator.<br><br>         17. Subject has a history of necessary treatment with rescue benzodiazepines which is<br>             foreseen to continue during the study. Rescue benzodiazepines will not be allowed in<br>             this study (stable dosing with a benzodiazepine as (one of the) baseline<br>             anti-epileptic drug(s) is allowed).<br><br>         18. Concomitant use of acetazolamide, carbonic anhydrase inhibitors such as topiramate and<br>             drugs with anticholinergic activity.<br><br>         19. Current psychosis or moderate to severe depression, or use of anti-psychotic drugs,<br>             MAOIs, tricyclic antidepressants, benzodiazepine or barbiturate treatment for<br>             disorders other than epilepsy, and stimulants (amphetamine derivatives) within 28 days<br>             before the screening visit.<br><br>         20. Concomitant use of felbamate or use of felbamate within two months prior to Visit 1.<br><br>         21. Subject is unable to swallow capsules.<br><br>         22. Subject is not in general good health as determined by medical history, physical exam<br>             and screening laboratory results.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Subject is male or female and aged 12-65 years.<br><br>          2. Subject has at least eight days with at least one myoclonic seizure over the two<br>             months Baseline Period. Myoclonic seizures must occur in the context of IGE and may be<br>             accompanied by other primary generalized seizures, provided these are also consistent<br>             with a diagnosis of Idiopathic Generalized Epilepsy (IGE).<br><br>          3. Subject (or parent/caregiver, for subjects below the age of consent) is willing to<br>             sign an informed consent form. Subjects below the age of consent in their country,<br>             must where appropriate be willing to give informed (written or verbal) assent.<br>             Subjects from the age specified in local regulations will be required to sign an<br>             appropriate informed consent form.<br><br>          4. Subject is taking a stable regimen of one or two other AEDs for at least two weeks<br>             prior to Visit 1 (start of the Baseline Period).<br><br>          5. Subject has a clinical diagnosis of any type of idiopathic generalised epilepsy (IGE)<br>             which has myoclonic seizures (and which may be accompanied by other generalised<br>             seizure types), according to the International League Against Epilepsy (ILAE)<br>             Classification of Epileptic Seizures (1981) and the ILAE Classification of Epilepsies<br>             and Epileptic Syndromes (1989). Diagnosis should have been established by clinical<br>             history, electroencephalogram (EEG) and computed tomography/magnetic resonance imaging<br>             (CT/MRI) of the brain consistent with idiopathic generalised epilepsy. A CT/MRI scan<br>             should have been performed within five years of the screening visit or, if not<br>             available from this period, should be performed in the Baseline Period.<br><br>          6. EEG should have been performed within one year of the screening visit or, if not<br>             available from this period, should be performed in the Baseline Period.<br><br>          7. Female subjects are pre-menarchal, or if of childbearing potential, are not pregnant<br>             or lactating, or are post-menopausal.<br><br>          8. Female subjects of childbearing potential = 18 years must abide by one of the<br>             following medically acceptable contraceptive measures: oral contraception pill,<br>             contraceptive injections, implants or patches, intrauterine device in place for at<br>             least three months or vasectomised partner or abstinence throughout the study.<br>             Subjects <18 years and of childbearing potential must be either abstinent or willing<br>             to use one of the medically appropriate forms of contraception for the duration of the<br>             study.<br><br>        Exclusion Criteria:<br><br>          1. Subject has progressive or focal neurological disease (as determined by preexisting<br>             brain imaging such as CT or MRI performed maximally five years before the screening<br>             visit), or clinically significant organic disease.<br><br>          2. Subject has a history of, or results of clinical investigations (including EEG data)<br>             that are suggestive of, partial seizures as defined by the ILAE, including generalised<br>             tonic clonic seizures which are suspected to be secondarily generalised.<br><br>          3. Subjects with cryptogenic or symptomatic generalised epilepsy.<br><br>          4. Subjects with psychogenic seizures.<br><br>          5. Subject has a history of convulsive status epilepticus within a year of screening<br>             while complying with AEDs.<br><br>          6. Subject has a history of renal calculi or renal insufficiency (above the upper normal<br>             limits of creatinine).<br><br>          7. Subject has a known diagnosis of human immunodeficiency virus (HIV) or hepatitis B or<br>             C.<br><br>          8. Subject has a predisposing condition that might interfere with absorption,<br>             distribution, or excretion of zonisamide.<br><br>          9. Subject has a history of sensitivity to sulfonamide drugs or to zonisamide or any of<br>             its excipients.<br><br>         10. Subject has a recent history of excessive alcohol use or drug abuse.<br><br>         11. Subject has a history of suicide attempt in the five years before the screening visit.<br><br>         12. Subject has abnormal screening laboratory values that are clinically significant.<br><br>         13. Subject has a history of demonstrated non-compliance with treatment, or the subject or<br>             parent/caregiver can be reasonably expected not to be compliant with study procedures<br>             or to complete the study.<br><br>         14. Subject has participated in a study of an investigational drug or device within 30<br>             days prior to screening.<br><br>         15. Subject has received previous treatment with zonisamide.<br><br>         16. Subject is treated with ketogenic diet or vagus nerve stimulator.<br><br>         17. Subject has a history of necessary treatment with rescue benzodiazepines which is<br>             foreseen to continue during the study. Rescue benzodiazepines will not be allowed in<br>             this study (stable dosing with a benzodiazepine as (one of the) baseline<br>             anti-epileptic drug(s) is allowed).<br><br>         18. Concomitant use of acetazolamide, carbonic anhydrase inhibitors such as topiramate and<br>             drugs with anticholinergic activity.<br><br>         19. Current psychosis or moderate to severe depression, or use of anti-psychotic drugs,<br>             MAOIs, tricyclic antidepressants, benzodiazepine or barbiturate treatment for<br>             disorders other than epilepsy, and stimulants (amphetamine derivatives) within 28 days<br>             before the screening visit.<br><br>         20. Concomitant use of felbamate or use of felbamate within two months prior to Visit 1.<br><br>         21. Subject is unable to swallow capsules.<br><br>         22. Subject is not in general good health as determined by medical history, physical exam<br>             and screening laboratory results.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Subject is male or female and aged 12-65 years.<br><br>          2. Subject has at least eight days with at least one myoclonic seizure over the two<br>             months Baseline Period. Myoclonic seizures must occur in the context of IGE and may be<br>             accompanied by other primary generalized seizures, provided these are also consistent<br>             with a diagnosis of Idiopathic Generalized Epilepsy (IGE).<br><br>          3. Subject (or parent/caregiver, for subjects below the age of consent) is willing to<br>             sign an informed consent form. Subjects below the age of consent in their country,<br>             must where appropriate be willing to give informed (written or verbal) assent.<br>             Subjects from the age specified in local regulations will be required to sign an<br>             appropriate informed consent form.<br><br>          4. Subject is taking a stable regimen of one or two other AEDs for at least two weeks<br>             prior to Visit 1 (start of the Baseline Period).<br><br>          5. Subject has a clinical diagnosis of any type of idiopathic generalised epilepsy (IGE)<br>             which has myoclonic seizures (and which may be accompanied by other generalised<br>             seizure types), according to the International League Against Epilepsy (ILAE)<br>             Classification of Epileptic Seizures (1981) and the ILAE Classification of Epilepsies<br>             and Epileptic Syndromes (1989). Diagnosis should have been established by clinical<br>             history, electroencephalogram (EEG) and computed tomography/magnetic resonance imaging<br>             (CT/MRI) of the brain consistent with idiopathic generalised epilepsy. A CT/MRI scan<br>             should have been performed within five years of the screening visit or, if not<br>             available from this period, should be performed in the Baseline Period.<br><br>          6. EEG should have been performed within one year of the screening visit or, if not<br>             available from this period, should be performed in the Baseline Period.<br><br>          7. Female subjects are pre-menarchal, or if of childbearing potential, are not pregnant<br>             or lactating, or are post-menopausal.<br><br>          8. Female subjects of childbearing potential = 18 years must abide by one of the<br>             following medically acceptable contraceptive measures: oral contraception pill,<br>             contraceptive injections, implants or patches, intrauterine device in place for at<br>             least three months or vasectomised partner or abstinence throughout the study.<br>             Subjects <18 years and of childbearing potential must be either abstinent or willing<br>             to use one of the medically appropriate forms of contraception for the duration of the<br>             study.<br><br>        Exclusion Criteria:<br><br>          1. Subject has progressive or focal neurological disease (as determined by preexisting<br>             brain imaging such as CT or MRI performed maximally five years before the screening<br>             visit), or clinically significant organic disease.<br><br>          2. Subject has a history of, or results of clinical investigations (including EEG data)<br>             that are suggestive of, partial seizures as defined by the ILAE, including generalised<br>             tonic clonic seizures which are suspected to be secondarily generalised.<br><br>          3. Subjects with cryptogenic or symptomatic generalised epilepsy.<br><br>          4. Subjects with psychogenic seizures.<br><br>          5. Subject has a history of convulsive status epilepticus within a year of screening<br>             while complying with AEDs.<br><br>          6. Subject has a history of renal calculi or renal insufficiency (above the upper normal<br>             limits of creatinine).<br><br>          7. Subject has a known diagnosis of human immunodeficiency virus (HIV) or hepatitis B or<br>             C.<br><br>          8. Subject has a predisposing condition that might interfere with absorption,<br>             distribution, or excretion of zonisamide.<br><br>          9. Subject has a history of sensitivity to sulfonamide drugs or to zonisamide or any of<br>             its excipients.<br><br>         10. Subject has a recent history of excessive alcohol use or drug abuse.<br><br>         11. Subject has a history of suicide attempt in the five years before the screening visit.<br><br>         12. Subject has abnormal screening laboratory values that are clinically significant.<br><br>         13. Subject has a history of demonstrated non-compliance with treatment, or the subject or<br>             parent/caregiver can be reasonably expected not to be compliant with study procedures<br>             or to complete the study.<br><br>         14. Subject has participated in a study of an investigational drug or device within 30<br>             days prior to screening.<br><br>         15. Subject has received previous treatment with zonisamide.<br><br>         16. Subject is treated with ketogenic diet or vagus nerve stimulator.<br><br>         17. Subject has a history of necessary treatment with rescue benzodiazepines which is<br>             foreseen to continue during the study. Rescue benzodiazepines will not be allowed in<br>             this study (stable dosing with a benzodiazepine as (one of the) baseline<br>             anti-epileptic drug(s) is allowed).<br><br>         18. Concomitant use of acetazolamide, carbonic anhydrase inhibitors such as topiramate and<br>             drugs with anticholinergic activity.<br><br>         19. Current psychosis or moderate to severe depression, or use of anti-psychotic drugs,<br>             MAOIs, tricyclic antidepressants, benzodiazepine or barbiturate treatment for<br>             disorders other than epilepsy, and stimulants (amphetamine derivatives) within 28 days<br>             before the screening visit.<br><br>         20. Concomitant use of felbamate or use of felbamate within two months prior to Visit 1.<br><br>         21. Subject is unable to swallow capsules.<br><br>         22. Subject is not in general good health as determined by medical history, physical exam<br>             and screening laboratory results.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Subject is male or female and aged 12-65 years.<br><br>          2. Subject has at least eight days with at least one myoclonic seizure over the two<br>             months Baseline Period. Myoclonic seizures must occur in the context of IGE and may be<br>             accompanied by other primary generalized seizures, provided these are also consistent<br>             with a diagnosis of Idiopathic Generalized Epilepsy (IGE).<br><br>          3. Subject (or parent/caregiver, for subjects below the age of consent) is willing to<br>             sign an informed consent form. Subjects below the age of consent in their country,<br>             must where appropriate be willing to give informed (written or verbal) assent.<br>             Subjects from the age specified in local regulations will be required to sign an<br>             appropriate informed consent form.<br><br>          4. Subject is taking a stable regimen of one or two other AEDs for at least two weeks<br>             prior to Visit 1 (start of the Baseline Period).<br><br>          5. Subject has a clinical diagnosis of any type of idiopathic generalised epilepsy (IGE)<br>             which has myoclonic seizures (and which may be accompanied by other generalised<br>             seizure types), according to the International League Against Epilepsy (ILAE)<br>             Classification of Epileptic Seizures (1981) and the ILAE Classification of Epilepsies<br>             and Epileptic Syndromes (1989). Diagnosis should have been established by clinical<br>             history, electroencephalogram (EEG) and computed tomography/magnetic resonance imaging<br>             (CT/MRI) of the brain consistent with idiopathic generalised epilepsy. A CT/MRI scan<br>             should have been performed within five years of the screening visit or, if not<br>             available from this period, should be performed in the Baseline Period.<br><br>          6. EEG should have been performed within one year of the screening visit or, if not<br>             available from this period, should be performed in the Baseline Period.<br><br>          7. Female subjects are pre-menarchal, or if of childbearing potential, are not pregnant<br>             or lactating, or are post-menopausal.<br><br>          8. Female subjects of childbearing potential = 18 years must abide by one of the<br>             following medically acceptable contraceptive measures: oral contraception pill,<br>             contraceptive injections, implants or patches, intrauterine device in place for at<br>             least three months or vasectomised partner or abstinence throughout the study.<br>             Subjects <18 years and of childbearing potential must be either abstinent or willing<br>             to use one of the medically appropriate forms of contraception for the duration of the<br>             study.<br><br>        Exclusion Criteria:<br><br>          1. Subject has progressive or focal neurological disease (as determined by preexisting<br>             brain imaging such as CT or MRI performed maximally five years before the screening<br>             visit), or clinically significant organic disease.<br><br>          2. Subject has a history of, or results of clinical investigations (including EEG data)<br>             that are suggestive of, partial seizures as defined by the ILAE, including generalised<br>             tonic clonic seizures which are suspected to be secondarily generalised.<br><br>          3. Subjects with cryptogenic or symptomatic generalised epilepsy.<br><br>          4. Subjects with psychogenic seizures.<br><br>          5. Subject has a history of convulsive status epilepticus within a year of screening<br>             while complying with AEDs.<br><br>          6. Subject has a history of renal calculi or renal insufficiency (above the upper normal<br>             limits of creatinine).<br><br>          7. Subject has a known diagnosis of human immunodeficiency virus (HIV) or hepatitis B or<br>             C.<br><br>          8. Subject has a predisposing condition that might interfere with absorption,<br>             distribution, or excretion of zonisamide.<br><br>          9. Subject has a history of sensitivity to sulfonamide drugs or to zonisamide or any of<br>             its excipients.<br><br>         10. Subject has a recent history of excessive alcohol use or drug abuse.<br><br>         11. Subject has a history of suicide attempt in the five years before the screening visit.<br><br>         12. Subject has abnormal screening laboratory values that are clinically significant.<br><br>         13. Subject has a history of demonstrated non-compliance with treatment, or the subject or<br>             parent/caregiver can be reasonably expected not to be compliant with study procedures<br>             or to complete the study.<br><br>         14. Subject has participated in a study of an investigational drug or device within 30<br>             days prior to screening.<br><br>         15. Subject has received previous treatment with zonisamide.<br><br>         16. Subject is treated with ketogenic diet or vagus nerve stimulator.<br><br>         17. Subject has a history of necessary treatment with rescue benzodiazepines which is<br>             foreseen to continue during the study. Rescue benzodiazepines will not be allowed in<br>             this study (stable dosing with a benzodiazepine as (one of the) baseline<br>             anti-epileptic drug(s) is allowed).<br><br>         18. Concomitant use of acetazolamide, carbonic anhydrase inhibitors such as topiramate and<br>             drugs with anticholinergic activity.<br><br>         19. Current psychosis or moderate to severe depression, or use of anti-psychotic drugs,<br>             MAOIs, tricyclic antidepressants, benzodiazepine or barbiturate treatment for<br>             disorders other than epilepsy, and stimulants (amphetamine derivatives) within 28 days<br>             before the screening visit.<br><br>         20. Concomitant use of felbamate or use of felbamate within two months prior to Visit 1.<br><br>         21. Subject is unable to swallow capsules.<br><br>         22. Subject is not in general good health as determined by medical history, physical exam<br>             and screening laboratory results.<br>